(0A2V.L)

. Currency in USD
Add to watchlist
- (-)
Full screen
Previous closeN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's rangeN/A - N/A
52-week rangeundefined - undefined
VolumeN/A
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Yahoo Finance UK

    Trending tickers: Anglo American, GameStop, Vodafone, Greggs and Novavax

    The latest investor updates on stocks that are trending on Tuesday.

  • Simply Wall St.

    Exploring Three Dividend Stocks On Euronext Paris

    Amidst a backdrop of rising optimism in European markets, where indices like France's CAC 40 have recently seen significant gains, investors are increasingly attentive to opportunities that promise not only growth but also stability. Dividend stocks, known for providing regular income alongside potential capital appreciation, are particularly appealing in this context as they offer a dual advantage in a fluctuating economic environment.

  • GlobeNewswire

    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

    ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeut